Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07621237 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
A Phase 2 study, sponsored by Tonix Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT07621237 is a Phase 2 study that is actively recruiting participants, run by Tonix Pharmaceuticals. The registered enrollment target is 360 participants.
The verdict
NCT07621237, a Phase 2 study, is actively recruiting participants, sponsored by Tonix Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL? Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder. Participants will: Take TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests
Interventions
- DRUG Placebo sublingual tablet
- DRUG TNX-102 SL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07621237
The ClinicalTrials.gov registry entry for NCT07621237 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo sublingual tablet is the first listed.
NCT07621237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07621237 about?
NCT07621237 is a clinical study titled "A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)". The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depr...
What is the current status of trial NCT07621237?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2026-06. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07621237?
The interventions under investigation include: Placebo sublingual tablet (DRUG), TNX-102 SL (DRUG).
Who is sponsoring clinical trial NCT07621237?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.